Avid Bioservices Inc (CDMO)

[north40000]

nuke661, from my previous post to which you responded:

"While oncology will be an important area, virology and the liver are clearly areas where Gilead will seek to maintain a lead.

The firm is developing GS-5374, a therapeutic treatment for Ebola – recently supplying the investigational drug on a compassionate use basis to treat the British nurse Pauline Cafferkey, whose Ebola infection had returned.

Cafferkey has now recovered from her second life-threatening episode. Bischofberger says Gilead knows it will never make money on the drug, but points out that it represents its commitment to global public health, particularly in the developing world.


Perhaps the same fate lay ahead for PPHM, notwithstanding new knowledge it might have gained from:

"http://www.hindawi.com/journals/jir/2015/347903/

Free access:

"Journal of Immunology Research
Volume 2015 (2015), Article ID 347903, 9 pages
http://dx.doi.org/10.1155/2015/347903

Research Article
Effective Binding of a Phosphatidylserine-Targeting Antibody to Ebola Virus Infected Cells and Purified Virions
S. D. Dowall,1 V. A. Graham,1 K. Corbin-Lickfett,2 C. Empig,2 K. Schlunegger,2 C. B. Bruce,1 L. Easterbrook,1 and R. Hewson1

1Public Health England, Porton Down, Wiltshire, Salisbury SP4 0JG, UK
2Peregrine Pharmaceuticals, Inc., Tustin, CA 92780, USA

Received 25 February 2014; Revised 20 June 2014; Accepted 3 September 2014

Academic Editor: Caroline Rowland

Copyright © 2015 S. D. Dowall et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Abstract

Ebola virus is responsible for causing severe hemorrhagic fevers, with case fatality rates of up to 90%. Currently, no antiviral or vaccine is licensed against Ebola virus. A phosphatidylserine-targeting antibody (PGN401, bavituximab) has previously been shown to have broad-spectrum antiviral activity. Here, we demonstrate that PGN401 specifically binds to Ebola virus and recognizes infected cells. Our study provides the first evidence of phosphatidylserine-targeting antibody reactivity against Ebola virus.[more]